drugset / Trial / NCT01959412

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

NCT01959412

Phase 2 Completed 91 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.

Timeline

Start
2013-11
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 27.5 ug Inhaled
Subject Indacaterol Other / unclassified 37.5 ug Inhaled
Subject Indacaterol Other / unclassified 55 ug Inhaled
Subject Indacaterol Other / unclassified 75 ug Inhaled
Subject Indacaterol Other / unclassified 150 ug Inhaled

Indications